Kevin Finney

Vice President of Business Development
Allergan, Inc.

Mr. Finney joined Allergan in January 2006 with over 20 years of experience managing corporate development and commercial operations. Mr. Finney has substantial licensing, partnering, and M&A experience from both the buy-side and the sell-side and has been directly responsible for a number of successful partnerships. In Mr. Finney’s current role as Vice President, Business Development he oversees Allergan’s Neurology, Urology, Neurotoxin and Alliance Management corporate activities. Prior to joining Allergan, Mr. Finney served in various business and commercial operations roles from 2000 – 2005 at Prometheus Laboratories and Amylin Pharmaceuticals. Prior to that Mr. Finney held various commercial positions at Parke-Davis division of Warner-Lambert from 1991 through the acquisition of Parke-Davis by Pfizer in 2000. Mr. Finney received a Bachelor’s Degree in Exercise Physiology from Cal State University, Long Beach and a MBA from Pepperdine University.

Check out the incredible speaker line-up to see who will be joining Kevin.

Download The Latest Agenda

Day 3

Tuesday, May 10th, 2016

09:35 PANEL: Best Practices For Alternative M&A Financing, Including Structured And Contingent Value Right (CVR) Transactions

• With the trend over the last couple years towards moving away from traditional M&A, what other transactions are surfacing and working well?

• Explaining the deal framework of a CVR transaction

• Exploring how CVRs have been designed and negotiated between the buy side and the sell side, including what achievement milestones have been put in place

• Exploring a consultant’s role in arranging CVR agreements and how they have seen them shift over the last year or two